Klotz L - Search Results

1

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

Rolfes L, Pawlitzki M, Pfeuffer S, Nelke C, Lux A, Pul R, Kleinschnitz C, Kleinschnitz K, Rogall R, Pape K, Bittner S, Zipp F, Warnke C, Goereci Y, Schroeter M, Ingwersen J, Aktas O, Klotz L, Ruck T, Wiendl H, Meuth SG. Rolfes L, et al. Among authors: klotz l. Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5):e1035. doi: 10.1212/NXI.0000000000001035. Print 2021 Sep. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34261812 Free PMC article.

2

Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.

Klotz L, Meuth SG, Wiendl H. Klotz L, et al. Clin Immunol. 2012 Jan;142(1):25-30. doi: 10.1016/j.clim.2011.04.006. Epub 2011 Apr 15. Clin Immunol. 2012. PMID: 21550857 Review.

3

[Diagnosis of multiple sclerosis 2010 revision of the McDonald criteria].

Klotz L, Gold R, Hemmer B, Korn T, Zipp F, Hohlfeld R, Kieseier BC, Wiendl H. Klotz L, et al. Nervenarzt. 2011 Oct;82(10):1302-9. doi: 10.1007/s00115-011-3283-x. Nervenarzt. 2011. PMID: 21681517 German. No abstract available.

4

Monoclonal antibodies in neuroinflammatory diseases.

Klotz L, Wiendl H. Klotz L, et al. Expert Opin Biol Ther. 2013 Jun;13(6):831-46. doi: 10.1517/14712598.2013.767329. Epub 2013 Mar 22. Expert Opin Biol Ther. 2013. PMID: 23521026 Review.

5

[Alemtuzumab for relapsing-remitting multiple sclerosis. Results of two randomized controlled phase III studies].

Klotz L, Meuth SG, Kieseier B, Wiendl H. Klotz L, et al. Nervenarzt. 2013 Aug;84(8):984-94. doi: 10.1007/s00115-013-3814-8. Nervenarzt. 2013. PMID: 23793409 Clinical Trial. German.

6

FTY720 (fingolimod) treatment tips the balance towards less immunogenic antigen-presenting cells in patients with multiple sclerosis.

Luessi F, Kraus S, Trinschek B, Lerch S, Ploen R, Paterka M, Roberg T, Poisa-Beiro L, Klotz L, Wiendl H, Bopp T, Jonuleit H, Jolivel V, Zipp F, Witsch E. Luessi F, et al. Among authors: klotz l. Mult Scler. 2015 Dec;21(14):1811-22. doi: 10.1177/1352458515574895. Epub 2015 Mar 2. Mult Scler. 2015. PMID: 25732840

7

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Klotz L, Grützke B, Eveslage M, Deppe M, Gross CC, Kirstein L, Posevitz-Fejfar A, Schneider-Hohendorf T, Schwab N, Meuth SG, Wiendl H. Klotz L, et al. BMC Neurol. 2015 Jun 23;15:96. doi: 10.1186/s12883-015-0354-9. BMC Neurol. 2015. PMID: 26099927 Free PMC article.

8

[Current aspects of therapy conversion for multiple sclerosis].

Kolber P, Luessi F, Meuth SG, Klotz L, Korn T, Trebst C, Tackenberg B, Kieseier B, Kümpfel T, Fleischer V, Tumani H, Wildemann B, Lang M, Flachenecker P, Meier U, Brück W, Limmroth V, Haghikia A, Hartung HP, Stangel M, Hohlfeld R, Hemmer B, Gold R, Wiendl H, Zipp F. Kolber P, et al. Among authors: klotz l. Nervenarzt. 2015 Oct;86(10):1236-47. doi: 10.1007/s00115-015-4368-8. Nervenarzt. 2015. PMID: 26269289 Review. German.

9

Implications of dietary salt intake for multiple sclerosis pathogenesis.

Hucke S, Wiendl H, Klotz L. Hucke S, et al. Among authors: klotz l. Mult Scler. 2016 Feb;22(2):133-9. doi: 10.1177/1352458515609431. Epub 2015 Oct 7. Mult Scler. 2016. PMID: 26447064 Review.

10

Sodium chloride promotes pro-inflammatory macrophage polarization thereby aggravating CNS autoimmunity.

Hucke S, Eschborn M, Liebmann M, Herold M, Freise N, Engbers A, Ehling P, Meuth SG, Roth J, Kuhlmann T, Wiendl H, Klotz L. Hucke S, et al. Among authors: klotz l. J Autoimmun. 2016 Feb;67:90-101. doi: 10.1016/j.jaut.2015.11.001. Epub 2015 Nov 14. J Autoimmun. 2016. PMID: 26584738

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,045 results

Search Page